Publication Name	World Journal of Clinical Oncology
Manuscript ID	63343
Country	Switzerland

Received	2021-01-27 14:14
Peer-Review Started	2021-01-27 14:15
To Make the First Decision
Return for Revision	2021-03-01 02:55
Revised	2021-03-05 20:48
Second Decision	2021-04-07 12:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-04-07 17:35
Articles in Press	2021-04-07 17:35
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-04-14 14:41
Publish the Manuscript Online	2021-04-20 12:49

ISSN	2218-4333 (online)
Open Access	Chevallier M and Borgeaud M contributed equally to this work; the concept was from Addeo A and Friedlaender A; all authors participated in drafting, editing the manuscript, read and approve the final manuscript.
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
Manuscript Source	Invited Manuscript
All Author List	Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo and Alex Friedlaender
ORCID	Author(s) ORCID Number Mathieu Chevallier http://orcid.org/0000-0002-7672-9063 Maxime Borgeaud http://orcid.org/0000-0003-1262-5641 Alfredo Addeo http://orcid.org/0000-0001-7802-1248 Alex Friedlaender http://orcid.org/0000-0003-1956-6824
Funding Agency and Grant Number
Corresponding Author	Alex Friedlaender, MD, Professor, Department of Oncology, University Hospital Geneva, 4 rue Gabrielle-Perret Gentil, Geneva 1205, Switzerland. alex.friedlaender@hcuge.ch
Key Words	Non-small cell lung cancer; Driver mutations; Tyrosine kinase inhibitors; Targeted agents; Oncogenes
Core Tip	We have reviewed the current literature about the impact of detecting oncogenic mutations in non-small cell lung cancer (NSCLC). Over the years, the adoption of next generation sequencing has rendered it easier to determine and detect possible oncogenic driver mutations, leading to the development of several targeted therapies. The clinical impact and benefit for patients is important in terms of quality and quantity of life. These therapies are more effective than standard chemotherapy treatment. We have reviewed the data to explain what has been done, is ongoing and shall be done in the future for patients with oncogene-driven NSCLC.
Publish Date	2021-04-20 12:49
Citation	Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future. World J Clin Oncol 2021; 12(4): 217-237
URL	https://www.wjgnet.com/2218-4333/full/v12/i4/217.htm
DOI	https://dx.doi.org/10.5306/wjco.v12.i4.217

Full Article (PDF)	WJCO-12-217.pdf
Full Article (Word)	WJCO-12-217.docx
Manuscript File	63343_Auto_Edited_LM.docx
Answering Reviewers	63343-Answering reviewers.pdf
Audio Core Tip	63343-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	63343-Conflict-of-interest statement.pdf
Copyright License Agreement	63343-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	63343-Language certificate.pdf
Peer-review Report	63343-Peer-review(s).pdf
Scientific Misconduct Check	63343-Bing-Ma YJ-1.jpg
Scientific Misconduct Check	63343-Bing-Fan JR-2.png
Scientific Misconduct Check	63343-Scientific misconduct check.pdf
Scientific Editor Work List	63343-Scientific editor work list.pdf